A KFF analysis of Medicare Advantage data found that only about 11% of denied prior authorizations are appealed — but when patients and providers do appeal, roughly 81% of denials are overturned. For GLP-1 receptor agonists, the denial rate is even higher and the appeal success rate is strong when the evidence package is built correctly. The problem is not that GLP-1 therapy lacks supporting evidence. The SELECT trial alone showed a 20% reduction in major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease. The STEP-HFpEF trial showed clinically meaningful improvement in heart failure symptoms. The FLOW trial demonstrated a 24% reduction in major kidney disease events.
The problem is that the initial PA submission often fails to connect this evidence to the patient's specific clinical picture, and the appeal repeats the same error. This article explains how to build a GLP-1 appeal evidence package that addresses cardiometabolic comorbidity denials — the fastest-growing category of GLP-1 PA rejection in 2025–2026.
This article is for provider-office access coordinators, manufacturer hub teams, reimbursement specialists, and market access professionals who support GLP-1 appeal workflows. It does not provide medical advice to patients.
Why cardiometabolic comorbidity denials are increasing
GLP-1 PA denial patterns have shifted between 2024 and 2026. Initially, most denials fell into three categories: BMI threshold not met, step therapy not completed, or weight management excluded from the plan's formulary. As formularies have tightened — CVS Caremark removed Zepbound from its standard commercial formulary effective July 2025, making Wegovy the preferred GLP-1 — and as more payers have adopted structured PA criteria, a new denial category has emerged: the patient has a cardiometabolic comorbidity that the payer does not recognize as qualifying, or the provider has not documented the comorbidity in a way that satisfies the payer's criteria.
Common cardiometabolic comorbidity denial scenarios:
| Denial scenario | What the payer says | What is actually happening |
|---|---|---|
| "Not medically necessary" | BMI and comorbidities do not meet criteria | The patient has CVD, HFpEF, or CKD, but the documentation does not specify the diagnosis with sufficient detail |
| "Step therapy required" | Patient must try older weight-loss medications first | The provider prescribed for a cardiometabolic indication (e.g., cardiovascular risk reduction) but the PA was coded as weight management, triggering step-therapy rules |
| "Cosmetic use" | Request appears to be for cosmetic weight loss | The PA narrative focused on weight loss rather than cardiometabolic risk reduction, and the reviewer classified it accordingly |
| "Insufficient documentation" | Clinical information is incomplete | BMI records, comorbidity ICD-10 codes, lab values, or prior treatment history are missing or inconsistent |
| "Diagnosis mismatch" | Prescribed drug does not match diagnosis | The drug was prescribed under the obesity indication, but the patient's primary clinical need is cardiovascular or renal, and the PA did not bridge the two |
The evidence package structure
A strong GLP-1 appeal for cardiometabolic comorbidity has five components. Each maps to a specific denial reason and a specific evidence source.
Component 1: The clinical picture — matching patient to criteria
The appeal must present the patient's clinical status in the exact terms the payer uses in its coverage criteria. This means:
- Correct ICD-10 codes for every qualifying comorbidity, not just the primary diagnosis. If the patient has HFpEF, hypertension, and prediabetes, all three should appear on the problem list in the submission.
- Objective measurements that confirm each coded diagnosis. An echocardiogram report for HFpEF, lab results for CKD staging, blood pressure readings for hypertension, HbA1c for prediabetes.
- BMI documented at the time of therapy initiation (for Medicare GLP-1 Bridge) or at the most recent visit (for commercial PA), with the calculation method and source.
- Treatment history showing what therapies have been tried, failed, or are contraindicated — with dates, doses, and outcomes for each.
Component 2: The clinical trial evidence — citing the right trial for the right indication
GLP-1 clinical trials are not interchangeable. Each trial tested a specific drug in a specific population for a specific endpoint. Citing the wrong trial weakens the appeal. The table below maps the indication to the supporting trial:
| Indication | Drug | Trial | Key result | Citation |
|---|---|---|---|---|
| Cardiovascular risk reduction in obesity/CVD | Wegovy (semaglutide 2.4 mg) | SELECT (NEJM 2023) | 20% reduction in MACE (CV death, nonfatal MI, nonfatal stroke) vs placebo | Lincoff et al., NEJM 2023;389:2221-2232 |
| Heart failure with preserved ejection fraction + obesity | Wegovy (semaglutide 2.4 mg) | STEP-HFpEF (NEJM 2023) | 16.6-point KCCQ-CSS improvement vs 8.7 for placebo; 13.3% weight loss | Kosiborod et al., NEJM 2023;389:1069-1082 |
| Chronic kidney disease + T2D | Ozempic (semaglutide 1 mg) | FLOW (NEJM 2024) | 24% reduction in major kidney disease events | Perkovic et al., NEJM 2024;391:109-121 |
| Obstructive sleep apnea + obesity | Zepbound (tirzepatide) | SURMOUNT-OSA | Significant reduction in apnea-hypopnea index events | Lilly press release, 2024 |
| Weight management + obesity | Wegovy (semaglutide 2.4 mg) | STEP 1 (NEJM 2022) | 14.9% body weight reduction vs 2.4% for placebo | Wilding et al., NEJM 2022;386:205-216 |
| Weight management + obesity | Zepbound (tirzepatide) | SURMOUNT-1 (NEJM 2022) | 20.9% body weight reduction vs 3.1% for placebo | Jastreboff et al., NEJM 2022;387:205-216 |
The appeal should reference the trial that matches the patient's indication. If a patient has established CVD and obesity, citing SELECT (not STEP 1) frames the request as cardiovascular risk reduction, not cosmetic weight loss. This distinction is the single most powerful reframing tool in a GLP-1 appeal.
Component 3: The letter of medical necessity — what it must say
A Letter of Medical Necessity (LMN) is the narrative bridge between the clinical picture and the trial evidence. The LMN should be written by the prescribing provider and must include:
- Patient identification — name, date of birth, member ID, and group number.
- Diagnosis statement — every qualifying ICD-10 code with a brief clinical description.
- BMI and history — current BMI or BMI at therapy initiation, weight trajectory, and duration of overweight/obesity.
- Prior treatments attempted and failed — a specific list: "Patient attempted phentermine 37.5 mg daily from January to March 2025 with inadequate response (2 lb weight loss). Patient completed 6 months of supervised diet and exercise program with 3 lb weight loss, followed by regain." Dates, doses, and outcomes matter more than generic statements.
- Comorbidity impact statement — how the comorbid condition affects the patient clinically. For example: "The patient has NYHA class II heart failure with preserved ejection fraction (LVEF 55% per echocardiogram dated March 2026) with dyspnea on exertion limiting ambulation to 2 blocks. KCCQ-CSS score is 52, indicating significant functional limitation."
- Clinical trial citation — reference the specific supporting trial by name and key finding.
- Drug-specific rationale — why this specific GLP-1 agent is appropriate, including any relevant contraindications to alternatives.
- Treatment plan — dose titration schedule, monitoring plan, and expected clinical endpoints.
The LMN should not simply assert "this medication is medically necessary." It should prove medical necessity by connecting the patient's documented clinical state to the evidence base and the payer's own coverage criteria.
Component 4: The payer criteria crosswalk
Most commercial payers publish their GLP-1 coverage criteria as clinical policies available on their websites. The appeal should explicitly crosswalk the patient's documentation to each criterion:
| Payer criterion | Patient documentation | Source |
|---|---|---|
| BMI ≥ 30 or BMI ≥ 27 with comorbidity | BMI 32 recorded at visit of March 15, 2026 | Office visit vital signs |
| Documented weight-related comorbidity | Heart failure with preserved ejection fraction, NYHA class II, LVEF 55% | Echocardiogram report, cardiology note |
| Prior weight loss attempt | Completed 6-month supervised lifestyle program (Jan–Jun 2025) | Program enrollment records, provider notes |
| Step therapy requirement | Tried and failed phentermine 37.5 mg (Jan–Mar 2025) and orlistat 120 mg (Apr–Jun 2025) | Pharmacy fill records, provider notes |
| Lifestyle modification ongoing | Currently enrolled in nutrition counseling and exercise program | Dietician referral, program records |
This crosswalk format demonstrates to the reviewer that every criterion has been addressed, reducing the chance of a second denial for "incomplete information."
Component 5: The peer-to-peer preparation
When the written appeal is denied, the next step is a peer-to-peer (P2P) review — a phone call between the prescribing provider and the payer's medical director. P2P reviews are most effective when:
- The denial was based on medical necessity and the initial submission did not fully capture clinical complexity.
- The chart tells a more complete story than the records that were submitted.
- The denial cites "incomplete information" rather than a hard clinical exclusion.
P2P requests typically must be made within 5–10 business days of the denial. The provider should prepare by:
- Reviewing the denial letter for the exact stated reason.
- Having the full chart available during the call, including notes that were not in the initial submission.
- Being ready to discuss the patient's clinical trajectory and why alternative treatments are inadequate.
- Referencing the specific clinical trial evidence for the patient's indication.
Special scenarios
Appeal when the payer considers GLP-1 "cosmetic"
This is the most common framing error. When the PA focuses on weight loss rather than cardiometabolic risk, the reviewer classifies the request as cosmetic. The appeal must reframe:
- Shift the narrative from "weight loss" to "cardiovascular risk reduction" (citing SELECT), "heart failure symptom improvement" (citing STEP-HFpEF), or "chronic kidney disease progression slowing" (citing FLOW).
- Include the comorbidity ICD-10 codes as primary diagnoses, not secondary to obesity.
- Have the LMN explicitly state the cardiometabolic indication as the primary reason for prescribing.
Appeal when step therapy was not completed
Many 2025–2026 policies require documentation of prior use or intolerance of older weight-loss medications (phentermine, orlistat, combinations) before approving a GLP-1. If step therapy was not completed:
- Document contraindication to the required step-therapy agent (e.g., "phentermine contraindicated due to uncontrolled hypertension").
- Document adverse reaction to a prior trial of the step-therapy agent.
- Cite clinical guidelines (Endocrine Society, AACE) that support GLP-1 as first-line therapy for patients with specific cardiometabolic comorbidities.
Appeal after formulary exclusion
If the payer has excluded the requested GLP-1 from its formulary entirely (as CVS Caremark did with Zepbound from July 2025 through September 2026, before adding it back as a preferred option effective October 1, 2026), the appeal pathway may be limited:
- Request a formulary exception with clinical justification for why the preferred alternative (e.g., Wegovy instead of Zepbound) is contraindicated or has been tried and failed.
- Document any prior adverse reaction to the preferred formulary agent.
- If the patient has a documented history of stable response to the excluded drug, cite continuity-of-care concerns.
Timeline and deadlines
GLP-1 appeal timelines vary by payer type:
| Payer type | Internal appeal deadline | Decision timeline | External review |
|---|---|---|---|
| Commercial (fully insured) | 180 days from denial | 30 days (pre-service) | 4 months from internal denial |
| ERISA self-funded | Per plan document | 30 days (pre-service), 60 days (post-service) | 4 months from internal denial |
| Medicare Advantage | 60 days from denial | 30 days (standard), 72 hours (expedited) | Per Medicare Part C appeals process |
| Medicaid | Per state rules | 30 days (standard), 24 hours (expedited) | Per state fair hearing process |
For urgent cases where treatment delay poses health risk, request an expedited review. Insurers are legally required to respond within 72 hours for urgent appeals.
What to monitor
- Payer policy updates. GLP-1 coverage criteria change frequently. A policy that denied coverage in Q1 may approve it in Q3 after formulary updates. Check the payer's clinical policy webpage before every appeal.
- New indication approvals. Wegovy's HFpEF indication (expected FDA decision 2025–2026) will create a new, explicitly covered diagnosis pathway that bypasses the "weight management" PA track.
- Medicare GLP-1 Bridge. Starting July 1, 2026, eligible Medicare beneficiaries access GLP-1 drugs through a separate demonstration program with its own PA process — not through standard Part D plan PA.
- State biomarker and coverage mandates. States with biomarker or insurance coverage mandates may provide additional appeal leverage.
Sources
- CMS. "Medicare GLP-1 Bridge." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp1-bridge
- Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389(24):2221-2232. (SELECT trial) https://pubmed.ncbi.nlm.nih.gov/37952107/
- Kosiborod MN et al. "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity." N Engl J Med. 2023;389(12):1069-1082. (STEP-HFpEF trial) https://pubmed.ncbi.nlm.nih.gov/37952108/
- Perkovic V et al. "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes." N Engl J Med. 2024;391(2):109-121. (FLOW trial) https://pubmed.ncbi.nlm.nih.gov/38630892/
- Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2022;386(3):205-216. (STEP 1 trial) https://pubmed.ncbi.nlm.nih.gov/35241829/
- Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1 trial) https://pubmed.ncbi.nlm.nih.gov/35658024/
- Novo Nordisk. "Navigating Appeals and Denials for Wegovy." novoMEDLINK resource. https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/documents/US25SEMO02476_DenialsandAppealsGuide.pdf
- IntuitionLabs. "GLP-1 Market Access: PBM Prior Auth & First-Fill Metrics." 2026. https://intuitionlabs.ai/articles/glp-1-pbm-market-access-prior-authorization-benchmarks
- PlexusDx. "Zepbound Prior Authorization 2026 Guide." https://plexusdx.com/blogs/learn/zepbound-prior-authorization-plexusdx
- Oana Health. "GLP-1 Insurance Denials: What to Do." https://www.oanahealth.com/post/glp-1-insurance-denials-what-to-do
Last updated May 31, 2026. This article is for informational purposes only and does not constitute medical advice, reimbursement guidance, or legal counsel. Coverage criteria and appeal processes vary by payer, plan, and state.
